November 30, 2020

The Niche

Knoepfler lab stem cell blog

Fujifilm

2 min read

Cynata Therapeutics Limited has received approval from UK regulators to start a first-of-its-kind allogeneic IPSC-based trial of MSCs for graft versus host disease (GVHD). Cynata also had some big news a couple weeks back with a deal with Fujifilm. The company is aiming to recruit 16 patients to test whether the MSCs (a type of adult stem cell) made from pluripotent stem cells created in the lab is safe and eventually whether it can aid patients facing GVHD, a potentially life threatening consequence of bone …Read More

2 min read

It seems like Fridays are always a good time for reflection. It’s not like the scientist’s week ends on Friday sad to say, but still at least we can pause momentarily TGIF style and reflect on the maelstrom that is our lives, while cracking open another diet Coke or pouring another cup of coffee. This week was a great one for getting into some intense discussions with other scientists both in person and electronically. CRISPR the talk of the biology town. Everyone is talking …Read More

4 min read

The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did its IPO with an initial offering of about $46 million. Fujifilm reportedly has a multibillion-dollar war chest for buying into the life sciences sector and a growing interest in regenerative …Read More